非布司他治疗慢性肾脏病伴高尿酸血症的有效性及安全性评价
Efficacy and Safety Evaluation of Febuxoat in the Treatment of Chronic Kidney Disease with Hyperuricemia
梁森林 1李娟 1高甄典 1李永刚 1唐伯玉1
作者信息
- 1. 涟水县人民医院肾内科,江苏 涟水 223400
- 折叠
摘要
目的 评价非布司他治疗慢性肾脏病(chronic kidney disease,CKD)伴高尿酸血症(hyperuricemia,HUA)的有效性及安全性.方法 目的选取2022年1月—2023年12月涟水县人民医院收治的62例CKD伴HUA患者,按治疗方法不同分为对照组(别嘌醇治疗,31例)与干预组(非布司他治疗,31例),比较两组的疗效、尿酸水平、不良反应发生率.结果 干预组的总有效率96.77%(30/31)高于对照组的74.19%(23/30),差异有统计学意义(χ2=4.679,P<0.05);治疗 1个月、3个月,干预组尿酸水平优于对照组,差异有统计学意义(P均<0.05);干预组的总不良反应率低于对照组,差异有统计学意义(P<0.05).结论 非布司他应用于CKD伴HUA患者治疗中的效果较好,安全性高,不良反应发生率低.
Abstract
Objective To evaluate the efficacy and safety of febuxoat in the treatment of chronic kidney disease(CKD)with hyperuricemia(HUA).Methods A total of sixty-two patients with CKD and HUA treated in Lianshui County People's Hospital from January 2022 to December 2023 were objectively selected and divided into control group(allo-purine treatment,thirty-one cases)and intervention group(febulistat treatment,thirty-one cases)according to differ-ent treatment methods.The efficacy,uric acid level and incidence of adverse reactions of the two groups were com-pared.Results The intervention group total effective was 96.77%(30/31)higher than 74.19%(23/31)of the control group,the difference was statistically significant(χ2=4.679,P<0.05).After 1 month and 3 months of treatment,the uric acid levels in the intervention group were better than those in the control group,the differences were statistically significant(both P<0.05).The total adverse reaction rate of intervention group was lower than that of the control group,the differences were statistically significant(P<0.05).Conclusion Febuxostat is effective in the treatment of CKD pa-tients with HUA,with high safety and low incidence of adverse reactions.
关键词
非布司他/慢性肾脏病/高尿酸血症/有效性/安全性Key words
Febuxostat/Chronic kidney disease/Hyperuricemia/Effectiveness/Security引用本文复制引用
出版年
2024
NETL
NSTL
万方数据